Hospital Hotel Dieu
- Address
- 1 Place Alexis Ricordeau, 44000 Nantes, France
Female Urogenital & Pregnancy Complications
At Hospital Hotel Dieu in Nantes, the obstetrics team conducts trials aimed at improving outcomes for pregnant women, especially those undergoing assisted reproductive technology. The primary focus is on preventing preeclampsia and reducing preterm birth.
- Aspirin prophylaxis study for preeclampsia prevention
- Evaluation of maternal and fetal health markers
- Assessment of safety in nulliparous women after ART
The trial involves three investigators and reflects the site’s commitment to maternal health research.
Immune System Disorders
Researchers at the gynécologie obstétrique department are exploring novel therapies for autoimmune skin conditions, notably alopecia areata. The study tests the oral Janus kinase inhibitor upadacitinib to determine its long‑term efficacy and safety in both adults and adolescents.
- Double‑blind evaluation of two dose levels
- Extended treatment phase up to 52 weeks
- Dose‑adjustment strategy based on response criteria
With three investigators, the program seeks to expand therapeutic options for severe hair‑loss disorders.
Dermatologic Signs & Symptoms
A separate trial at Hospital Hotel Dieu assesses the monoclonal antibody rocatinlimab for moderate‑to‑severe atopic dermatitis in teenage participants, measuring improvement with the Eczema Area and Severity Index.
- Randomized, placebo‑controlled design
- Primary endpoint at week 24
- Focus on safety and quality‑of‑life outcomes
The study adds to the site’s portfolio of dermatology research and involves the same three investigators.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 33 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Celgene Corp.1active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Celgene Corp.2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Hotel Dieu
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) | Amgen Inc. | Phase III | Not Recruiting | May 2023 | Jul 2025 |
IMP list
lock Showing 1 of 33 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide Monohydrate | 2 | Unknown | 2023-09-25 | 2025-12-19 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.